Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

What Was Tested

The paper reports a study of Receptors, Somatotropin, published as a randomized controlled trial.

Pegvisomant is a genetically engineered growth hormone-receptor antagonist that blocks the action of growth hormone.

Who Took Part

The abstract describes 112 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Receptors, Somatotropin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Receptors, Somatotropin.

A placebo (an inactive look-alike) gave the Receptors, Somatotropin group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Adenoma, Autoantibodies, Human Growth Hormone, Insulin-Like Growth Factor I, Pituitary Neoplasms and Receptors, Somatotropin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Receptors, Somatotropin in 112 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (The New England journal of medicine), a journal based in United States.

More context: all human trials.